The man who named the science: Dr. Parris M. Kidd

When we named this company ImmunoCeutica, we were reaching for a word that captured something precise. Immune system. Nutraceuticals. Evidence-based support for immunity. We thought we had coined something new.

As it turns out there was a pioneer before us. And the person who got there first, decades ahead of us, was a biochemist named Dr. Parris M. Kidd, PhD.

Dr. Kidd introduced the term "immunoceutical" in a 1999 article published in Total Health Magazine. When we subsequently learned of Dr Kidd’s work, it felt like his description of what immunoceuticals are and how they work, reads like it was written to describe us.

A real validation of our work at ImmunoCeutica! 

A word with a history

Dr. Kidd defined immunoceuticals as nutraceuticals that support the body's immune defenses - nutritional substances he described as better tolerated than pharmaceuticals and with far fewer adverse effects.

His framing was careful: not magic bullets, not replacements for medical care, but compounds that help the body's own immune defenses function at a higher level.

"The driving force of immunoceuticals is helping the body's immune system to help itself."- Dr. Parris M. Kidd, PhD, 1999

That sentence, written over 25 years ago, is as good a description of our philosophy as anything we could write today.

Mushroom extracts: 25 years ahead of the mainstream

Perhaps most striking is where Dr. Kidd began his survey of the evidence: mushroom beta-glucans.

In 1999, he described the beta-D-glucans in functional mushrooms as among the "foremost proven immunoceuticals," noting that preparations from Coriolus versicolor, Lentinus edodes (shiitake), and other species had already gone through double-blind clinical trials in Japan and elsewhere.

Same compounds. Same mechanisms. Same evidence base that sits behind MycoGuard today. The macrophage activation he described, and its downstream effects on T cells, B cells, and natural killer cells, is the same cascade decades of later research have kept validating.

Those extracts now draw serious clinical attention and a growing body of human trial data. What Dr. Kidd saw clearly in 1999, the supplement industry is only now catching up to.

The broader vision

The article goes well past mushrooms: phytosterols, adaptogenic herbs like Astragalus and Eleuthero, thymus extracts, transfer factors, antioxidant cofactors. He gathered them all under one idea, immunopotentiation.

The argument is simple. Give the immune system the right nutritional support, with real clinical evidence behind it, and it works at a higher level. Not tricked. Not bypassed. Supported.

That distinction still matters, and it maps onto how we work. We say "research suggests" for the same reason Dr. Kidd took care to separate the proven from the unproven: honest language is the only kind that holds up.

A word with a life of its own

Dr. Kidd has spent decades bridging nutritional biochemistry and mainstream medicine, writing about phosphatidylserine, omega-3s, CoQ10, and cellular health long before any of those entered common conversation. He is still at it. He serves as Technical Editor and Quality Matters Program Advisor at the Institute for Natural Medicine, and has spent a career arguing for exactly the thing the supplement industry needs more of: rigorous evidence behind what goes in the bottle.

"Immunoceutical" never caught on the way his other contributions did. Finding out he coined it left us somewhere between humbled and validated. Humbled, because we thought we had made something up. Validated, because arriving at the same word from a different starting point suggests the idea itself is sound.

A note on this article: We're sharing Dr. Kidd's 1999 piece as a historical reference and out of respect for work that got there early. The science he drew on, and in places anticipated, still shapes how we think about immune support. If this field interests you, his wider body of work is worth seeking out.

Twenty-five years on, the word he gave us still fits.